HQY vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HQY presents a stark divergence between strong fundamental earnings performance and bearish market sentiment. The company maintains a stable financial health profile with a Piotroski F-Score of 4/9 and excellent liquidity (Current Ratio 3.27). While the current price of $77.96 trades at a premium to its intrinsic value ($72.57) and Graham Number ($37.04), the Forward P/E of 14.60 suggests significant expected earnings expansion. However, the bullish fundamental outlook is heavily countered by a 0/100 technical trend and consistent insider selling.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HQY vs MRK: Head-to-Head Comparison
This page compares HealthEquity, Inc. (HQY) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.